Home Cart Sign in  
Chemical Structure| 1313712-90-1 Chemical Structure| 1313712-90-1
Chemical Structure| 1313712-90-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations      Show More

Shiqi Wang ; Changwei Yang ; Wentao Zhang ; Sheng Zhao ; Jiahuan You ; Ruisi Cai , et al.

Abstract: Transdermal microneedle-mediated glucose-responsive insulin delivery systems can modulate insulin release based on fluctuations in blood glucose levels, thus maintaining normoglycemia effectively in a continuous, convenient, and minimally invasive manner. However, conventional microneedles are limited by the low drug loading capacity, making it challenging to be applied on human skin at a reasonable size for a lasting glucose-controlling effect, thus hindering their clinical translation. Here, we design a microneedle patch with a solid insulin powder core to achieve a high loading capacity of insulin (>70 wt %) as well as a glucose-sensitive polymeric shell to realize glucose-responsive insulin release. Once exposed to hyperglycemia, the formation of negatively charged glucose−boronate complexes increases the charge density of the shell matrix, leading to swelling of the shell and accelerating insulin release from the core. We have demonstrated that this glucose-responsive microneedle patch could achieve long-term regulation of blood glucose levels in both type 1 diabetic mice and minipigs (up to 48 h with patches of ∼3.5 cm2 for minipigs >25 kg).

Keywords: drug delivery ; insulin ; glucose responsive ; microneedles ; diabetes

Purchased from AmBeed:

Sheng, Tao ; Jin, Rui ; Yang, Changwei ; Qiu, Ke ; Wang, Mingyang ; Shi, Jiaqi , et al.

Abstract: Timely administration of key medications toward patients with sudden diseases is critical to saving lives. However, slow transport of first-aid therapeutics and the potential absence of trained people for drug usage can lead to severe injuries or even death. Herein, an unmanned aerial vehicle (UAV)-mediated first-aid system for targeted delivery (uFAST) is developed. It allows unattended administration of emergency therapeutics-loaded transdermal microneedle (MN) patches toward patients to relieve symptoms by a contact-triggered microneedle applicator (CTMA). The implementability and safety of the uFAST for first aid is demonstrated in a severe hypoglycemic pig model by automatically delivering a glucagon patch with immediate and bioresponsive dual release modes. This platform technique may facilitate the development of UAV-mediated first-aid treatments for other sudden diseases.

Keywords: drug delivery ; first aid ; microneedles ; unmanned aerial vehicles

Purchased from AmBeed:

Yang, Changwei ; Sheng, Tao ; Hou, Wenhui ; Zhang, Juan ; Cheng, Li ; Wang, Hao , et al.

Abstract: Insulin and glucagon secreted from the pancreas with dynamic balance play a vital role in regulating blood glucose levels. Although distinct glucose-responsive insulin delivery systems have been developed, the lack of a self-regulated glucagon release module limits their clin. applications due to the potential risk of hypoglycemia. Here, we describe a transdermal polymeric microneedle patch for glucose-responsive closed-loop insulin and glucagon delivery to achieve glycemic regulation with minimized risk of hypoglycemia. The glucose-responsive phenylboronic acid units can bind to glucose to reversibly shift the net charge (from pos. to neg.) of the entire polymeric matrix within microneedles. Therefore, the release ratio of the neg. charged insulin and the pos. charged glucagon analog from the patch can be dynamically tuned upon the fluctuation of blood glucose levels to realize glycemic homeostasis. In both chem. induced type 1 diabetic mouse and minipig models, this glucose-responsive dual-hormone microneedle patch demonstrated tight long-term regulation in blood glucose levels (>24 h in minipigs).

Purchased from AmBeed:

Alternative Products

Product Details of (4-((2-Acrylamidoethyl)carbamoyl)-3-fluorophenyl)boronic acid

CAS No. :1313712-90-1
Formula : C12H14BFN2O4
M.W : 280.06
SMILES Code : OB(O)C1=CC(F)=C(C(NCCNC(C=C)=O)=O)C=C1
MDL No. :MFCD32856191
InChI Key :VROCFBAGKYSGGQ-UHFFFAOYSA-N
Pubchem ID :89138009

Safety of (4-((2-Acrylamidoethyl)carbamoyl)-3-fluorophenyl)boronic acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H312-H332
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P363-P501
 

Historical Records

Technical Information

Categories